Compare ResMed Inc. (RMD) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Union Pacific Corporation — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Union Pacific Corporation trades at $278.34 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 5.2× ResMed Inc.'s market cap, and Union Pacific Corporation pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Union Pacific Corporation for 105 Days on average.
| RMD | UNP | |
|---|---|---|
Market Cap | $31.89B | $165.27B |
Volume | 618,314 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $275.96 | $310.62 |
52-Week Low | $182.82 | $216.37 |
Typical Hold Time | 51 Days | 105 Days |
Enterprise Value | $31.24B | $194.33B |
Dividend Yield | 1.16% | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Union Pacific (UNP) trades at $278.20, up 1.28% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company maintains robust profitability with a 28.85% net margin and 39.7% ROE. Positive sentiment is driven by volume growth, a pending Norfolk Southern merger, and dividend reliability, though merger uncertainty and fuel costs pose risks.
Outlook is positive given earnings momentum and strategic initiatives, but investors face risks from merger execution and economic cyclicality. The stock offers value with a consensus price target of $332.10, implying significant upside, supported by stable cash flows and a solid dividend track record.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
